Get the Stockscreener App
48.19
2.38%
1.12
After Hours:
48.33
0.14
+0.29%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $48.19, with a volume of 34.69M.
It is up +2.38% in the last 24 hours and down -30.98% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$47.07
Open:
$48.27
24h Volume:
34.69M
Relative Volume:
2.73
Market Cap:
$163.37B
Revenue:
$43.59B
Net Income/Loss:
$15.04B
P/E Ratio:
14.27
EPS:
3.3766
Net Cash Flow:
$10.74B
1W Performance:
-32.79%
1M Performance:
-30.98%
6M Performance:
-42.94%
1Y Performance:
-63.62%
1-Day Range:
$47.55
$49.03
1-Week Range:
$46.90
$71.28
52-Week Range:
$46.90
$139.74
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.19 | 209.15B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Kessler Topaz Meltzer & Check, LLP - GlobeNewswire Inc.
How to monitor Novo Nordisk A s (b Shares) Adrhedged with trend dashboardsFree Portfolio Diversification Stock Ideas - Newser
Is Novo Nordisk A s (b Shares) Adrhedged Stock a Smart Buy in 2025 Investment Analysis InsideIntraday Strategy with Real Time Monitoring - Newser
When is Novo Nordisk A s (b Shares) Adrhedged stock expected to show significant growthExpert Picks Review With Low Risk - jammulinksnews.com
Real time scanner hits for Novo Nordisk A s (b Shares) Adrhedged explainedFree Access to Real-Time Trade Insights - Newser
Is Novo Nordisk A s (b Shares) Adrhedged trending in predictive chart modelsFree Breakout Confirmation With Entry Tracker - Newser
Novo Nordisk A s (b Shares) Adrhedged’s volatility index tracking explainedSmart Chart Forecasting with AI Algorithms - Newser
Is Novo Nordisk A s (b Shares) Adrhedged a growth stock or a value stockBreakout Stocks Tracker For Consistent Profits - jammulinksnews.com
Is Novo Nordisk A s (b Shares) Adrhedged stock overvalued or undervaluedExpert Picks Outlook To Watch Now - jammulinksnews.com
Earnings visualization tools for Novo Nordisk A s (b Shares) AdrhedgedSwing Trade Watchlist with Entry Zones - Newser
Why Novo Nordisk A s (b Shares) Adrhedged stock attracts strong analyst attentionIntraday Price Action Forecast Planner - Newser
Will Novo Nordisk A s (b Shares) Adrhedged benefit from macro trendsFree Oversold Recovery Opportunity Stocks - Newser
The stock price plunged more than 20% when Novo Nordisk, the developer of the famous obesity drug We.. - 매일경제
Will earnings trigger a reversal in Novo Nordisk A s (b Shares) AdrhedgedFree News Based Entry Opportunity Alerts - Newser
The stock price plunged more than 20% as Novo Nordisk, the developer of the famous obesity drug WeGo.. - 매일경제
Using AI based signals to follow Novo Nordisk A s (b Shares) AdrhedgedTrading Volume Spike and Reversal Analysis - Newser
Will Novo Nordisk A s (b Shares) Adrhedged Benefit From Broader Market BounceTriple Return Setup With Risk Control Explained - metal.it
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
Novo Nordisk Falls On Lowered Guidance. Pharma Giant Names New CEO. - Investor's Business Daily
Novo Nordisk ADR: Navigating Market Fluctuations with a 181.64B Market Cap - investchronicle.com
Bollinger Bands Show Potential Breakout in Novo Nordisk A s (b Shares) AdrhedgedProfit Target Stock Opportunity Monitor Activated - metal.it
Wall Street Today: Nasdaq, S&P hit record high; Sofi, Novo Nordisk, UnitedHealth shares in focus after Q2 results - MSN
Novo Nordisk Slumps While Philips Shines In European ADRs - Finimize
Novo Nordisk: Lower 2025 Guidance Reflects Persistent Competition From Compounded Semaglutide - Morningstar
Novo Nordisk: Lower 2025 Guidance Reflects Persistent Competition from Compounded Semaglutide - Morningstar
Novo Nordisk's Cardiometabolic Portfolio, Led by Semaglutide, Looks Underappreciated - Morningstar
Here’s What Happened The Last Time Novo Nordisk Stock Was This Oversold - Barchart.com
Published on: 2025-07-29 13:38:20 - metal.it
What institutional investors are buying Novo Nordisk A s (b Shares) Adrhedged stockLow Risk Forecasts For Smart Trading - jammulinksnews.com
How many analysts rate Novo Nordisk A s (b Shares) Adrhedged as a “Buy”Value Investing Entry Points With Proven Results - jammulinksnews.com
Published on: 2025-07-28 18:52:29 - beatles.ru
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):